September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Lung Cancer Incidence and Mortality Review Shows No Ethnic Differences in Women
January 7th 2016There are no differences in lung cancer incidence or mortality among women of different ethnic groups when adjusted for age, smoking, and other factors, according to an article recently published in the Journal of Clinical Oncology.
Read More
FDA Approves Non-Alcohol Formulation of Docetaxel for Multiple Cancer Types
December 29th 2015The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
Read More
Decision on Rociletinib for NSCLC Delayed by FDA
December 17th 2015The review period for rociletinib for EGFR T790M-positive non-small cell lung cancer (NSCLC) has been extended by the FDA by 3 months. The extension allows ample time to review additional data submitted by the drug's developer, Clovis Oncology.
Read More
Dr. William Wierda on Ibrutinib and Idelalisib as Treatments in NSCLC
December 9th 2015William G. Wierda, MD, PhD, discusses ibrutinib and idelalisib as treatments for non-small cell lung cancer. Wierda says that as it currenlty stands, ibrutinib is approved only for patients with NSCLC with a 17p deletion untreated and idelalisib is only approved for patients with untreated NSCLC.
Watch
Dr. Suresh Ramalingam on Immune Checkpoint Inhibitors in NSCLC Treatment
November 20th 2015Dr. Suresh Ramalingam on sequencing immune checkpoint inhibitors with chemotherapy in NSCLC treatment. He adds that a new class of agents can be given in conjunction with immune checkpoint inhibitors, such as IDO inhibitors.
Watch
New Options Possible in Patients With NSCLC and Brain Metastases
November 16th 2015A study published in the Journal of Clinical Oncology found that an EGFR inhibitor, erlotinib, was well tolerated in combination with whole-brain radiation therapy for patients with brain metastases from NSCLC.
Read More
ALK-Rearranged NSCLC Brain Metastasis Study Demonstrates Extended Survival
November 16th 2015A paper presenting the results of a retrospective study of patients with ALK-rearranged NSCLC hypothesized that prognosis for patients with NSCLC and brain metastases could be further identified through molecular subtyping.
Read More
Dr. Chandra P. Belani on the Importance of Immunotherapies in Treating Lung Cancer
November 14th 2015Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, talks about how immunotherapies targeting PD-L1 and PD-1 are showing activity in lung cancer.
Watch
Osimertinib Approved by FDA for EGFR T790M-Positive NSCLC
November 13th 2015The FDA has given osimertinib (Tagrisso, AZD9291) an accelerated approval for treatment of patients with advanced EGFR T790M mutation-positive non-small cell lung cancer (NSCLC) following progression on a prior EGFR TKI.
Read More
Dr. Gregory Riely on Potential Treatment for Patients With MET Exon 14 Mutation
November 4th 2015Gregory J. Riely, MD, PhD, vice chair of the Clinical Trials Office in the Department of Medicine, Memorial Sloan Kettering Cancer Center, talks about non-small cell lung cancer (NSCLC) MET exon 14 mutations and their response to drugs like cabozantinib and crizotinib.
Watch